Stoke Therapeutics, Inc. (STOK) DCF Valuation

Stoke Therapeutics, Inc. (STOK) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Stoke Therapeutics, Inc. (STOK) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Looking to determine the intrinsic value of Stoke Therapeutics, Inc.? Our STOK DCF Calculator integrates real-world data with extensive customization features, allowing you to adjust forecasts and enhance your investment strategy.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 12.4 8.8 8.1 7.5 7.0 6.5 6.0
Revenue Growth, % 0 0 0 0 -29.22 -7.31 -7.31 -7.31 -7.31 -7.31
EBITDA -35.2 -50.3 -83.6 -102.8 -112.3 1.6 1.5 1.4 1.3 1.2
EBITDA, % 100 100 100 -828.78 -1279.09 20 20 20 20 20
Depreciation .5 1.9 2.2 3.5 2.5 5.8 5.4 5.0 4.6 4.3
Depreciation, % 100 100 100 28.5 28.12 71.32 71.32 71.32 71.32 71.32
EBIT -35.7 -52.2 -85.8 -106.3 -114.8 1.6 1.5 1.4 1.3 1.2
EBIT, % 100 100 100 -857.28 -1307.21 20 20 20 20 20
Total Cash 222.5 287.3 219.8 229.6 201.4 8.1 7.5 7.0 6.5 6.0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .3 .0 .1 .6 .1
Account Receivables, % 100 100 100 4.74 0.72893
Inventories .0 .0 .0 10.9 .0 6.3 5.9 5.4 5.0 4.7
Inventories, % 100 100 100 88.13 0 77.63 77.63 77.63 77.63 77.63
Accounts Payable .8 1.5 2.4 .8 1.7 5.3 4.9 4.6 4.2 3.9
Accounts Payable, % 100 100 100 6.17 19.31 65.1 65.1 65.1 65.1 65.1
Capital Expenditure -1.6 -1.1 -1.2 -4.0 -1.6 -.8 -.8 -.7 -.7 -.6
Capital Expenditure, % 100 100 100 -31.94 -18.41 -10.07 -10.07 -10.07 -10.07 -10.07
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -31.5 -50.6 -84.7 -98.0 -114.8 1.5 1.4 1.3 1.2 1.1
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -32.2 -48.7 -82.9 -111.4 -101.5 -1.1 6.5 6.0 5.6 5.2
WACC, % 8.9 8.91 8.91 8.9 8.91 8.9 8.9 8.9 8.9 8.9
PV UFCF
SUM PV UFCF 16.5
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 5
Terminal Value 76
Present Terminal Value 50
Enterprise Value 66
Net Debt -189
Equity Value 256
Diluted Shares Outstanding, MM 44
Equity Value Per Share 5.81

What You Will Get

  • Comprehensive STOK Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Real-Time Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Analysis: Evaluate various scenarios to assess Stoke Therapeutics’ future performance.
  • User-Friendly Interface: Designed for professionals while remaining easy for newcomers.

Key Features

  • Customizable Research Inputs: Adjust key variables such as revenue projections, R&D spending, and market penetration rates.
  • Instant DCF Analysis: Automatically computes intrinsic value, NPV, and additional metrics in real-time.
  • High-Precision Results: Leverages Stoke Therapeutics' actual financial data for accurate valuation assessments.
  • Effortless Scenario Testing: Easily explore various assumptions and evaluate their impacts side by side.
  • Efficiency Booster: Avoid the hassle of constructing intricate valuation models from the ground up.

How It Works

  • 1. Access the Template: Download and open the Excel file containing Stoke Therapeutics, Inc.'s preloaded data.
  • 2. Modify Assumptions: Adjust key parameters such as growth rates, WACC, and capital expenditures.
  • 3. Observe Results Instantly: The DCF model automatically computes intrinsic value and NPV.
  • 4. Evaluate Scenarios: Analyze various forecasts to explore different valuation results.
  • 5. Present with Assurance: Deliver professional valuation insights to guide your strategic decisions.

Why Choose This Calculator for Stoke Therapeutics, Inc. (STOK)?

  • User-Friendly Interface: Tailored for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters effortlessly to suit your analysis needs.
  • Real-Time Feedback: Monitor immediate changes to Stoke Therapeutics' valuation as you modify inputs.
  • Pre-Configured Data: Comes with Stoke Therapeutics' actual financial metrics for swift evaluations.
  • Relied Upon by Experts: Employed by investors and analysts for making well-informed decisions.

Who Should Use This Product?

  • Investors: Accurately assess Stoke Therapeutics, Inc.'s (STOK) intrinsic value prior to making investment choices.
  • CFOs: Utilize a sophisticated DCF model for financial reporting and strategic analysis.
  • Consultants: Efficiently modify the template for client valuation reports.
  • Entrepreneurs: Acquire insights into the financial modeling practices of leading biotech firms.
  • Educators: Employ it as a resource to illustrate valuation techniques in the classroom.

What the Template Contains

  • Comprehensive DCF Model: Editable template featuring extensive valuation calculations.
  • Real-World Data: Stoke Therapeutics’ historical and projected financials preloaded for in-depth analysis.
  • Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
  • Dashboard with Visual Outputs: Visualizations including charts and tables for clear, actionable results.

No products were found matching.